MENU
+Compare
RPRX
Stock ticker: NASDAQ
AS OF
Aug 11, 04:59 PM (EDT)
Price
$36.18
Change
-$1.40 (-3.73%)
Capitalization
16.25B

RPRX Royalty Pharma plc Forecast, Technical & Fundamental Analysis

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties... Show more

RPRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for RPRX with price predictions
Aug 08, 2025

RPRX in downward trend: price may decline as a result of having broken its higher Bollinger Band on July 28, 2025

RPRX broke above its upper Bollinger Band on July 28, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 34 similar instances where the stock broke above the upper band. In of the 34 cases the stock fell afterwards. This puts the odds of success at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for RPRX moved out of overbought territory on August 06, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 similar instances where the indicator moved out of overbought territory. In of the 24 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 62 cases where RPRX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RPRX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on July 21, 2025. You may want to consider a long position or call options on RPRX as a result. In of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for RPRX just turned positive on July 28, 2025. Looking at past instances where RPRX's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where RPRX advanced for three days, in of 288 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 201 cases where RPRX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.560) is normal, around the industry mean (18.662). P/E Ratio (17.601) is within average values for comparable stocks, (54.033). Projected Growth (PEG Ratio) (3.269) is also within normal values, averaging (2.909). Dividend Yield (0.023) settles around the average of (0.049) among similar stocks. P/S Ratio (9.461) is also within normal values, averaging (286.048).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. RPRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RPRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
RPRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

RPRX is expected to report earnings to fall 12.44% to 99 cents per share on November 05

Royalty Pharma plc RPRX Stock Earnings Reports
Q3'25
Est.
$1.00
Q2'25
Beat
by $0.10
Q1'25
Missed
by $0.66
Q4'24
Missed
by $0.63
Q3'24
Missed
by $0.01
The last earnings report on August 06 showed earnings per share of $1.14, beating the estimate of $1.04. With 1.59M shares outstanding, the current market capitalization sits at 16.25B.
A.I.Advisor
published Dividends

RPRX is expected to pay dividends on September 10, 2025

Royalty Pharma plc RPRX Stock Dividends
A dividend of $0.22 per share will be paid with a record date of September 10, 2025, and an ex-dividend date of August 15, 2025. The last dividend of $0.22 was paid on June 10. Read more...
A.I. Advisor
published General Information

General Information

a provider of drug development services

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
110 East 59th Street
Phone
+1 212 883-0200
Employees
89
Web
https://www.royaltypharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
FSST29.000.29
+1.02%
Fidelity Sustainable U.S. Equity ETF
QIDX10.610.03
+0.28%
Indexperts Quality Earnings Focused ETF
AMZA42.650.03
+0.07%
InfraCap MLP ETF
KCCA15.530.01
+0.06%
KraneShares California Carbon Allw ETF
FLCB21.45-0.02
-0.09%
Franklin U.S. Core Bond ETF

RPRX and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, RPRX has been loosely correlated with SANA. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if RPRX jumps, then SANA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RPRX
1D Price
Change %
RPRX100%
+1.54%
SANA - RPRX
40%
Loosely correlated
-29.41%
INCY - RPRX
36%
Loosely correlated
+0.24%
GLPG - RPRX
33%
Loosely correlated
-0.97%
SEER - RPRX
33%
Loosely correlated
+14.43%
XNCR - RPRX
31%
Poorly correlated
-1.23%
More